Cancer immunotherapy has become an indispensable mode of treatment for a multitude of
solid tumor cancers. Colorectal cancer (CRC) has been one of the many cancer types to
benefit from immunotherapy, especially in advanced disease where standard treatment fails
to prevent recurrence or results in poor survival. The efficacy of immunotherapy in CRC has
not been without challenge, however, as early clinical trials observed dismal responses in
unselected CRC patients treated with checkpoint inhibitors. Many studies and clinical trials …